Search

Giant cell tumor (GCT) is a bone tumor that is encountered frequently and can have both benign and aggressive characteristics. It is commonly found in individuals between the ages of 20 and 45, with a slightly higher incidence in females. A 22-year-old female presented with a progressively increasing painful and tender lump in the distal forearm, along with restricted wrist movements and inability to use her right hand. The patient's medical history was complicated by the ongoing Syrian conflict, which limited her access to medical care and resources. Physical examination showed a large lump in the distal radius and severely restricted pronation and supination, additionally, Plain radiographs and computerized tomography (CT) were suggestive of an aggressive giant cell tumor (GCT) of the proximal humerus, which was confirmed on histopathological examination. After appropriate investigation, we decided to proceed with En bloc resecting and reconstructing the resultant defect with a proximal non-vascularized fibula graft. Despite the challenges posed by the Syrian conflict, our surgical intervention successfully restored the patient's arm function and provided her with a positive outcome. This case highlights the importance of adapting to difficult circumstances in order to provide necessary medical care to patients affected by conflict and other adverse situations.

COVID-19 complications present a huge burden on healthcare systems and warrant a predictive risk model for disease severity of SARS-CoV-2 infection to enable early intervention, prospective decision-making and triaging of patients. We profiled plasma proteins from COVID-19 patients (severe n=50, and mild n=50) and controls (n=50) using function- and pathway-based panels developed with the highly specific proximity extension assays. Several biological pathways were specific for patients with severe complications. Based on these dysregulated profiles, we propose candidate FDA-approved drugs that target multiple upregulated proteins to treat severe complications. In addition, the set of differentially expressed plasma proteins in severe disease contained a robust 46-protein signature, the COVID-19 molecular severity score, which predicts the risk of severe complications. We cross-validated this molecular severity score in an independent cohort and found it useful within three days after hospital admission to predict COVID-19 severity and outcomes. Associated with the molecular severity score, we identified a set of clinical parameters available at admission, that act as a clinical risk score for complications. The molecular and clinical risk scores described in our study may be prognostic tools for severe COVID-19 disease and help alleviate the pressure on healthcare systems during infection peaks.